Vitamin E-Conjugated Phosphopeptide Inhibitor of the Polo-Box Domain of Polo-Like Kinase 1
Authors:
- 30 October 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 16 (12) , 4867-4877
Abstract
No abstract availableKeywords
Funding Information
- National Research Council of Science and Technology (CAP-17-03-KRIBB)
- Korea Basic Science Institute (T39703)
This publication has 49 references indexed in Scilit:
- Passively Targeted Curcumin-Loaded PEGylated PLGA Nanocapsules for Colon Cancer Therapy In VivoSmall, 2015
- Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1Amino Acids, 2014
- Significance of Protein Binding in Pharmacokinetics and PharmacodynamicsJournal of Pharmaceutical Sciences, 2010
- Polo-box domain: a versatile mediator of polo-like kinase functionCellular and Molecular Life Sciences, 2010
- Doxorubicin conjugated to d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS): Conjugation chemistry, characterization, in vitro and in vivo evaluationBiomaterials, 2008
- In Vitro and In Vivo Investigation on PLA–TPGS Nanoparticles for Controlled and Sustained Small Molecule ChemotherapyPharmaceutical Research, 2008
- Hypoxia in cancer: significance and impact on clinical outcomeCancer and Metastasis Reviews, 2007
- Advances in the Use of Tocols as Drug Delivery VehiclesPharmaceutical Research, 2006
- Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugsBiomaterials, 2005
- Disruption of mitochondria during tocotrienol-induced apoptosis in MDA-MB-231 human breast cancer cellsBiochemical Pharmacology, 2004